EDEN

THE NATURAL SOLUTION

2018 PRELIMINARY RESULTS



ABOUT US

Eden Research provides sustainable solutions for challenges in three key industries:



〇〇〇 (子) ANIMAL HEALTH

LON:EDEN AIM listed since 2012 Market cap £21m

We have intellectual property and expertise in plant-derived sustainable chemistry, microencapsulation and formulation technologies.

Eden is the only UK listed company focused on biopesticides for sustainable agriculture.

Globally, Eden is one of few biocontrol companies with proven products and regulatory authorisation.

MEET THE TEAM



SEAN SMITH

CHIEF EXECUTIVE OFFICER Over 25 years experience in the speciality chemicals and industrial biotechnology industries

LYKELE VAN DER BROEK NON-EXECUTIVE CHAIRMAN



Formerly Board member of Bayer CropScience and President of Bayer Animal Health, both divisions of Bayer AG



ALEX ABREY CHIEF FINANCIAL OFFICER

Experienced Financial Director to a diverse range of businesses including financial and management consultancy



Our vision is to be **the leader in sustainable bioactive products** enabled or enhanced by our novel encapsulation and delivery technologies.

Our **strategy** is built on the following key pillars:



2018 HIGHLIGHTS



SIGNIFICANT MARKET POTENTIAL



UNIQUE TECHNOLOGY



SKILLED AND EXPERIENCED PROFESSIONALS



TRAJECTORY OF FINANCIAL GROWTH

COMMERCIAL, REGULATORY AND IP

Submission of first applications for the regulatory approval of active ingredients and products in the U.S. and Australia

Successful positioning of Mevalone as an early-season treatment contributing to product sales growth of 112% Regulatory trials supporting label extensions on crops and the authorisation in Central Europe for the treatment of botrytis on grapes

Robust results supporting the first use of Mevalone for post harvest applications



Sipcam Oxon SpA ("Sipcam") appointed as exclusive distributor for Mevalone in **ten new territories**

2018 HIGHLIGHTS











LEAR COMMERCIAL PROGRESS

SKILLED AND EXPERIENCED PROFESSIONALS

PRELIMINARY UNAUDITED FINANCIAL RESULTS

Revenue **£2.8m** (2017: £1.9m)

Upfront and milestone payments **£1.2m**

(2017: £1.1m)

Operating profit* **£0.02m** (2017: loss £0.6m)

Product sales increased 112% **£1.6m** (2017: £0.8m) Operating loss **£0.5m** (2017: £0.6m) Net cash **£2.5m** (2017: £3.7m)


* before non-cash share based payment charge, amortisation and royalties refund

OUR TECHNOLOGY

WE HAVE DEVELOPED A NATURAL FORMULATION TECHNOLOGY, SUSTAINETM

Particles are derived from **natural yeast cells**.

Sustaine encapsulates active ingredients and provides for the **sustained release** of these ingredients enabling their **safe, more efficient use**.



OUR TECHNOLOGY

WE HAVE DEVELOPED A NATURAL FORMULATION TECHNOLOGY, SUSTAINETM

Particles are derived from **natural yeast cells**.

Sustaine encapsulates active ingredients and provides for the **sustained release** of these ingredients enabling their **safe, more efficient use**.

Conventional methods of microencapsulation ("microplastics") are under increasing regulatory pressure and may be banned in the EU from 2020. **Sustaine will remain free from such restrictions.**

COST EFFECTIVE

USEFUL ACROSS A WIDE RANGE OF ACTIVE INGREDIENTS

> A HIGH CAPACITY DELIVERY SYSTEM


VERSATILE AND ROBUST

NATURAL AND SUSTAINABLE

SIMPLY PROCESSED AND USED WITH STANDARD EQUIPMENT

INDUSTRY APPLICATIONS

We work globally through multi-national and local partnerships to develop and launch solutions for challenges facing **three key industries**.




CROP PROTECTION MARKET

Conventional crop protection products face major challenges such as:

The global crop protection market is valued at approx. **\$58 billion in 2017** The biopesticide market is projected to reach **\$8.8 billion by 2022**

Consumer concernsIncreasingly challengingFarmers seekingover food safetyregulatory requirementseffective alternatives

Neonicotinoid insecticides were worth \$3.1 billion globally but are now facing withdrawal in Europe and elsewhere. Conventional crop protection products formulated with Sustaine and Eden's active ingredients can help address many of these issues.



CROP PROTECTION MARKET

The dominant molluscicide approved for use in the EU is **metaldehyde**. The UK banned metaldehyde in 2018. **AHDB estimates that a lack of slug control products will cost UK agriculture £100 million per year!**

The re-registration of **copper-based products** as fungicides was approved in the EU but a **33% reduction in use limit was imposed.**

New EU rules have prohibited any substance identified as an **Endocrine Disruptor** from being used in plant protection products. **The new rules will nonetheless have an impact upon the availability of insecticides and fungicides.**





PRODUCTS INCLUDE:



OUR PRODUCT FOCUS

Our focus is on crop protection, developing products based on sustainable chemistries to protect high-value crops from pests and disease, with equal or better performance when compared with conventional pesticides.

Critically, our products are exempt from pesticide residue limits and can be used up to the point of harvest giving growers reduced risk, maximum flexibility and security.





FUNGICIDES Botrytis, powdery mildew, downy mildew

NEMATICIDES Root knot

nematodes



white flies

INSECTICIDES MC Mites and S



MOLLUSCICIDES Slug and snail control

OUR CURRENT PRODUCT FOCUS

Our products harness the biocidal activity of naturally occurring molecules produced by plants as part of their defence systems. **These active ingredients are known as terpenes**.

Our biopesticides, formulated with Sustaine, add value compared to conventional pesticides by:

Enabling sustained delivery, increasing residual efficacy and reducing use rates

Tackling resistance build-up

Protecting plants from potentially damaging chemicals

Allowing solvent-free, stable formulations with high loadings of active ingredients

Naturally binding to plant and animal surfaces improving efficacy and retention

Providing flexible formulation options

Exemption from maximum residue levels

Low or no pre-harvest intervals giving growers maximum flexibility, security and control

PRODUCT COMMERCIALISATION

We now have commercial partners in place across six continents.



Securing patent protection for intellectual property



Developing our product pipeline



Gaining regulatory approval







Identifying suitable industrial partners





Investment in research and development




WHERE WE ARE NOW



WHERE WE ARE NOW

Product sales have commenced in key markets where we have authorization to market and sell our first product, Mevalone.






NEW PARTNERSHIPS AND REGULATORY ACTIVITY


Eden Research has regulatory clearance

for its first product in multiple countries with approval expected for its second product, Cedroz, in 2019.









SIGNIFICANT MARKET POTENTIAL



UNIQUE TECHNOLOGY CLEAR COMMERCIAL PROGRESS



KILLED AND EXPERIENCEE PROFESSIONALS



TRAJECTORY OF FINANCIAL GROWTH

A GROWING GLOBAL MARKET

- The global biopesticides market is projected to be worth more than \$8.8 billion by 2022
- The biopesticides market is growing at a CAGR of approximately 17% per annum
- Animal health market value estimated to exceed \$33 billion by 2020

Eden's proven addressable market today is more than \$1.2 billion.

Tomorrow this grows to more than \$2 billion, not including Sustaine.



SIGNIFICANT MARKET

POTENTIAL











SKILLED AND EXPERIENCED PROFESSIONALS




TRAJECTORY OF

SIGNIFICANT MARKET OPPORTUNITIES

High demand for sustainable products that can compete with conventional products on ease-of-use, efficacy, safety, cost and reliability

- Ongoing pressure on the conventional pesticides market, which is subject to increased scrutiny and regulatory pressures contributing to significant disruption
- Increasing time and cost of bringing new chemical products to market:
 12 years and around \$300 million

- Significantly lower costs of bringing biopesticides to market – around \$25-50 million
- Significant barriers to entry
- Major product withdrawals across all segments of the conventional crop protection industry are having a significant impact on growers leaving them with lower yields and declining productivity





SIGNIFICANT MARKET POTENTIAL LEAR COMMERCIAI PROGRESS



SKILLED AND EXPERIENCED PROFESSIONALS



TRAJECTORY OF FINANCIAL GROWTH

UNIQUE TECHNOLOGY

- Ownership of the patents behind the Sustaine encapsulation technology
- Significant investment in patent protection and the registration of new actives
- Proven efficacy with strong commercial validation by farmers and our partners
- Scope to exploit the core technologies beyond existing markets and products

Eden's products serve as sustainable alternatives to conventional chemicals without limitations such as residue limits, pest resistance, pre-harvest intervals, long field re-entry periods or increasing restrictions on use.

Residue-free crops command a higher value and have a significant commercial advantage in the valuable export markets.



CLEAR COMMERCIAL PROGRESS



SIGNIFICANT MARKET POTENTIAL



UNIQUE TECHNOLOGY



SKILLED AND EXPERIENCED PROFESSIONALS



TRAJECTORY OF FINANCIAL GROWTH

CLEAR COMMERCIAL PROGRESS

- Product sales continue to progress well with expansion into new markets
- Solid commercial pipeline
- Regulatory clearance for product sales across multiple countries with applications pending in 29 new countries
- Commercial and collaborative relationships with strong industry partners

- Significant investment in commercialisation by key partners
- Key crops growing from one to more than ten in the next three years
- Sales on two continents today - expanding to six in the coming years



SKILLED AND EXPERIENCED PROFESSIONALS



SIGNIFICANT MARKET POTENTIAL



UNIQUE TECHNOLOGY



CLEAR COMMERCIAL PROGRESS



TRAJECTORY OF FINANCIAL GROWTH

SKILLED AND EXPERIENCED PROFESSIONALS

Strong Board and management team

Lykele van der Broek appointed as Non-Executive Director and Chairman – former Board member and COO of Bayer CropScience Wealth of experience in the **agriculture**, **consumer products** and **animal health** sectors globally

Outsourcing of some functions to maintain a flexible, low overheard base



SIGNIFICANT MARKET POTENTIAL



UNIQUE

TECHNOLOGY

CLEAR COMMERCIAL PROGRESS






SKILLED AND EXPERIENCED PROFESSIONALS

TRAJECTORY OF FINANCIAL GROWTH

FINANCIAL POSITION

Increased revenue generation from product sales Significant investment by key partners Robust balance sheet and cash position





OUR PRIORITIES

COMMERCIAL GROWTH

- Regulatory clearance in new countries
- Revenue growth
- Partnerships for Mevalone in new territories
- Pursue collaboration with majors

RESEARCH, DEVELOPMENT AND OPERATIONS

- Supply chain optimisation
- Expansion of screening and field trials
- Accelerate commercialisation of Sustaine for conventional actives

BUSINESS LINE DIVERSIFICATION

- Bayer Animal Health commercial launches
- TerpeneTech product launches
- Pursue opportunities in the seed treatments market
- Expand crops and diseases treated
- Geographic diversification (seasonal and climatic variation)

STRENGTHENING AND GROWING THE TEAM

 Commercial, regulatory and technical roles

SUMMARY

01

Significant scope for further exploitation of the Company's core technologies beyond biopesticides and crop protection

03

Biological solutions are the fastest growing segment of the crop protection industry, and **Eden is the only UK-listed company with a focus on this market with proven products and a growing business** 02

04

Strong potential for Eden Research's current and pipeline products **across a broad segment of the crop protection industry** with new crop and disease targets under active evaluation

Large potential for growth in biopesticides, conventional pesticides, animal health and consumer products based on solid foundations and commercialisation to date

999 999 999









EDEN

THE NATURAL SOLUTION

THANK YOU